HAEMONETICS CORP (HAE) stock intrinsic value fair value estimate & owner earnings analysis

Haemonetics sells the devices and single-use kits that collect and process blood. Plasma (about 39% of fiscal 2026 revenue of $1.33 billion) is the NexSys PCS collection system and disposables used by plasma-donation centers; Blood Center (17%) is apheresis for platelets and red cells; Hospital (44%) is hemostasis testing (TEG), cell salvage and transfusion software, plus vascular closure (VASCADE), esophageal temperature management (Attune) and sensor-guided products. Placed devices pull through recurring disposables, which is the engine of the earnings. What we measured. We value the cash the business produces before its lenders are paid: operating cash flow, with working-capital swings removed, less stock compensation and the capital spending needed to stay in business, with interest added back. Two accounting points matter. First, Haemonetics builds equipment it places with customers out of inventory, and its filings show that cost as a non-cash transfer ($51.9 million in fiscal 2026, $21.1 million in 2025, $28.2 million in 2024) while the same amount flatters operating cash flow; we charge it as capital spending, which corrects an overstatement in our earlier work (previous figures are not comparable). Second, the $86.5 million fiscal 2026 write-down (mainly the Attune acquisition, plus HAS diagnostic intellectual property) is non-cash and added back, but it is evidence that recent acquisitions have not earned what was paid, and we credit no value to unproven acquisitions. Intangible amortization is about $44 million a year and does not reduce cash; no growth is credited to it. Earning power. Business cash flow was about $193 million in fiscal 2024, about $203 million in 2025 (excluding a one-time $10.6 million CSL shortfall payment) and $216 million in 2026, after the sale of the Whole Blood line (January 2025) and the end of CSL's North American disposables purchases. We anchor on the median of those three years, $203 million, about $4.45 per share on 45.7 million diluted shares. Fiscal 2026 growth was only 0.8%, so year one of the base case grows 0.8%, not more; the first quarter of fiscal 2027 (revenue up 5.6%) did not show cash flow clearly above the prior-year quarter, so we do not move the level. The ERP upgrade and equipment placements are real cash drains that the working-capital removal hides; the bear case charges them. Base case: business worth about $3.2 billion ($70 per share), owes about $1.0 billion ($22 per share), leaving about $48 per share. Cash flow grows 2% a year for years 2-10, below the ten-year revenue growth of about 4.7% and supported by realized price increases across all business units in fiscal 2026 and the recurring-disposables model through the 2020 shutdown. After year ten it holds flat for twenty years, then stops: the installed-base franchise in plasma and hospital blood management has persisted for decades and its research spending is already charged against earnings, but no named driver extends it further. Left out: vascular-closure share gains, the Vivasure PerQseal large-bore approval (still pending), market growth in plasma and TEG, and margin expansion. Bear case: business worth about $1.7 billion ($37 per share), owes about $1.08 billion ($24 per share, including about $72 million of extra cost refinancing at higher rates), leaving about $13 per share. Cash flow starts $30 million lower because the recurring outflow in other assets and liabilities (averaging $26 million a year over five years) is real. In year four a customer representing 13% of sales (the top ten customers are 44%) is lost; CSL's multi-year exit shows how this unfolds, and we take $45 million of annual cash flow off. In year six a repeat of the fiscal 2020-21 COVID shutdown cuts cash flow 39% (the actual fall, with revenue down 12%), then 25% and 10% below trend in the next two years. After year ten earnings erode 4% a year. Cash flow stays above the interest bill throughout (low point about $78 million against roughly $60 million of interest). Bull case: business worth about $4.3 billion ($94 per share), owes about $1.0 billion ($22 per share), leaving about $72 per share. Cash flow starts at the fiscal 2026 level of $216 million and grows 5% a year for ten years, in line with the ten-year revenue record and the 14.6% fiscal 2026 growth in Blood Management Technologies, then holds flat for twenty years. Debt. At June 27, 2026 the company had $1.19 billion of borrowings against $223 million of cash, after drawing its revolver to repay the $300 million 2026 convertible notes in March 2026. Essentially all of it falls due in 2029: the $250 million term loan and $750 million revolver mature April 30, 2029 (floating, about 5.6%), and the $700 million 2.5% convertible notes mature June 1, 2029 (conversion price $117.12, principal payable in cash). The bank agreement caps leverage at 4.0 times EBITDA. Net debt used is $1.19 billion less $123 million of cash above about $100 million kept for operations, less about $58 million for the cheap 2.5% coupon. The company has also authorized a $500 million buyback, which adds leverage. What would make this wrong. A second large plasma customer leaving sooner or faster than modeled, a deeper-than-expected downturn in donations or procedures before the 2029 refinancing, or equipment placement spending staying at fiscal 2026's $85 million level. Late in August 2026 the company reportedly announced a new non-exclusive CSL Plasma supply agreement; its terms are not in the filings, so no value is credited. Not reconciled: the fiscal 2026 filing does not name the customer behind the 13% concentration. Margin-of-safety price. We are fairly sure of the earnings level, since three years of cash flow sit within $193-216 million, but less sure it is permanent, because one plasma customer is 13% of sales, ten customers are 44%, the equipment-placement cost has swung between $21 million and $52 million a year, and all $1.19 billion of debt comes due within a few months in 2029. The worst plausible outcome is a lost major customer and a donation or procedure shock arriving as the debt is refinanced; the business would survive it (cash flow still covers interest) but the equity would be worth only about $13 per share, and a still worse combination could leave little. If we are wrong about the customer and the equipment spending, equity is worth about $13-25. The price assumes a five-year holding period, during which the business pays no dividend but retains roughly $150-160 million a year after interest (about $3.40 per share) to repay debt and buy back stock. The margin-of-safety price is $26: that is about a 13% yearly after-interest cash earning on the price, growing about 2%, so a 20% annual return needs the business value to be recognized over about four to five years, while a price much above this leaves no cushion for the 2029 refinancing and the customer concentration.